COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1585: Articles 15841-15850  | Next

The role of host cell glycans on virus infectivity: The SARS-CoV-2 case
Acosta Guitierrez, S., Buckley, J., Battaglia, G.
10.1101/2021.05.08.443212 — Posted: 2021-05-09
Mathematical Analysis and Topology of SARS-CoV-2, Bonding with Cells and Unbonding
S.R. Srinivasa Rao, A., Krantz, S.
10.1101/2021.05.07.443177 — Posted: 2021-05-09
Suppression of Global Protein Translation in SARS-CoV-2 Infection
Parthasarathy, H., Gupta, D., Suresh, A. P., Tandel, D., Sah, V., Harshan, K. H.
10.1101/2021.05.08.443207 — Posted: 2021-05-09
The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus
Yu, J., Dong, W., Li, A., Zhang, J., Caligiuri, M., Jaramillo, S., Mead, H. L., Stone, N. E., Jones, A., Kollath, D. R., Coyne, V. K., Yearsley, M., Wang, L.-S., Barker, B. M., Keim, P., Barr, T.
10.1101/2021.05.08.443244 — Posted: 2021-05-09
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E., Adams, L. J., Shi, P.-Y., Fremont, D. H., Curiel, D. T., Alter, G., Diamond, M. S.
10.1101/2021.05.08.443267 — Posted: 2021-05-09
Expansion of tissue-resident CD8+ T cells and CD4+ Th17 cells in the nasal mucosa following mRNA COVID-19 vaccination
Ssemaganda, A., Nguyen, H. M., Nuhu, F., Jahan, N., Card, C. M., Kiazyk, S., Severini, G., Keynan, Y., Su, R.-C., Ji, H., Abrenica, B., McLaren, P. J., Ball, B., Bullard, J., Van Caeseele, P., Stein, D., McKinnon, L.
10.1101/2021.05.07.442971 — Posted: 2021-05-09
In-vivo Protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice
Narayanappa, A., Engler-Chiurazzi, E. B., Murray-Brown, I. C., Gressett, T. E., Biose, I. J., Chastain, W. H., Bix, G.
10.1101/2021.05.08.443275 — Posted: 2021-05-09 Discussion: Onsite
Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection
Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Barnes, C. O., Cipolla, M., Ramos, V., Oliveira, T. Y., Cho, A., Schmidt, F., Silva, J. D., Bednarski, E., Daga, M., Turroja, M., Millard, K. G., Jankovic, M., Gazumyan, A., Bieniasz, P. D., Caskey, M., Hatziioannou, T., Nussenzweig, M. C.
10.1101/2021.05.07.443175 — Posted: 2021-05-09
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Ferreira, I., Datir, R., Papa, G., Kemp, S., Meng, B., Rakshit, P., Singh, S., Pandey, R., Ponnusamy, K., Radhakrishnan, V. S., INSACOG CONSORTIUM, , COG-UK CONSORTIUM, , Sato, K., James, L., Aggarwal, A., Gupta, R. K.
10.1101/2021.05.08.443253 — Posted: 2021-05-09 Discussion: Onsite
Cumulative incidence of SARS-CoV-2 infections among adults in Georgia, USA, August-December 2020
Chamberlain, A. T., Toomey, K. E., Bradley, H., Hall, E. W., Fahimi, M., Lopman, B. A., Luisi, N., Sanchez, T., Drenzek, C., Shioda, K., Siegler, A. J., Sullivan, P. S.
10.1101/2021.05.06.21256407 — Posted: 2021-05-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).